WO2017057973A1 - Novel ophthalmic composition comprising rebamipide and method for preparing the same - Google Patents

Novel ophthalmic composition comprising rebamipide and method for preparing the same Download PDF

Info

Publication number
WO2017057973A1
WO2017057973A1 PCT/KR2016/011015 KR2016011015W WO2017057973A1 WO 2017057973 A1 WO2017057973 A1 WO 2017057973A1 KR 2016011015 W KR2016011015 W KR 2016011015W WO 2017057973 A1 WO2017057973 A1 WO 2017057973A1
Authority
WO
WIPO (PCT)
Prior art keywords
ophthalmic composition
agent
rebamipide
present disclosure
composition
Prior art date
Application number
PCT/KR2016/011015
Other languages
French (fr)
Inventor
Eui-Hwan Cho
Sung-Ju Choi
Sung-Woo Lee
Hee-Jong Shin
Min-Hyo Ki
Mee-Hwa Choi
Dong-Ha Lee
Original Assignee
Samjin Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samjin Pharmaceutical Co., Ltd. filed Critical Samjin Pharmaceutical Co., Ltd.
Priority to JP2018516690A priority Critical patent/JP6625206B2/en
Priority to BR112018006474A priority patent/BR112018006474A2/en
Priority to US15/762,165 priority patent/US10918725B2/en
Priority to EP16852119.3A priority patent/EP3355929A4/en
Priority to MX2018003799A priority patent/MX2018003799A/en
Priority to CA3000634A priority patent/CA3000634C/en
Priority to CN201680056205.9A priority patent/CN108136036A/en
Priority to RU2018115669A priority patent/RU2706353C1/en
Publication of WO2017057973A1 publication Critical patent/WO2017057973A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Definitions

  • the present disclosure relates to an ophthalmic composition comprising rebamipide, which maintains its transparency, has excellent stability, and is easy to prepare, and a method for preparing the same.
  • Rebamipide [2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid] is a quinolone derivative represented by the following formula I.
  • Rebamipide is known to increase gastric mucin to have anti-inflammatory and antiulcer actions on the digestive tract and thus has been used as an oral therapeutic agent for gastric ulcer since 1990. Moreover, the effects of rebamipide on an increase of goblet cell density in eyes, an increase of mucin in eyes, and an increase of lacrimal fluid have been proven, and thus rebamipide has been developed and sold as a therapeutic agent for dry eye syndrome in the form of an ophthalmic solution in Japan.
  • rebamipide has low solubility in a pH range where it is applicable to the eye, which makes it difficult to maintain a stable and transparent aqueous solution during long-term storage and to manufacture in the form of a transparent ophthalmic solution, and thus is available in the form of an ophthalmic suspension.
  • the drug is dispersed as particles, which causes a feeling of irritation in the eye as well as local pain.
  • Research aimed at developing a transparent ophthalmic solution comprising rebamipide has continued to progress; however, it is believed that it is difficult to develop an aqueous preparation comprising rebamipide so far, and the products developed so far are in the form of an ophthalmic suspension.
  • a pharmaceutical composition comprising rebamipide, which maintains its transparency for a long time even in a physiologically neutral to weakly basic pH range (below 8) that does not injure the cornea and conjunctiva of a patient suffering from dry eye, and which has improved stability so as not to be re-dispersed.
  • An object of the present disclosure is to provide an ophthalmic composition comprising rebamipide, which is transparent in a pH range of 7 to 8. More specifically, an object of the present disclosure is to provide an ophthalmic composition comprising rebamipide, which maintains its transparency for a long time even in a physiologically neutral to weakly basic pH range that does not injure the cornea and conjunctiva of a patient suffering from dry eye, and which has improved stability so as not to be re-dispersed.
  • Another object of the present disclosure is to provide a method for preparing an ophthalmic composition of the present disclosure in a simple manner without any complicated process.
  • the present disclosure provides a novel ophthalmic composition comprising rebamipide and a method for preparing the same, which will be described in detail below.
  • Ophthalmic Composition Comprising Rebamipide
  • the ophthalmic composition of the present disclosure comprises (1) rebamipide, (2) an anti-recrystallizing agent selected from the group consisting of a cyclodextrin derivative, an amino acid, and mixtures thereof, and (3) a buffering agent.
  • Rebamipide may be prepared directly by a conventionally known method or commercially available.
  • the concentration of rebamipide may be 0.1 to 1.5 w/v%, preferably 0.2 to 1.0 w/v%.
  • the anti-recrystallizing agent used in the present disclosure is an additive to prevent a solution, which is sufficiently transparent but is present in a supersaturated state, from failing to maintain a transparent appearance without any precipitate being formed during long-term storage.
  • the anti-recrystallizing agent that can be used in the present disclosure includes a cyclodextrin derivative and/or an amino acid.
  • cyclodextrin derivative used as the anti-recrystallizing agent in the present disclosure examples include alpha-, beta-, and gamma-cyclodextrin, and substituted derivatives thereof such as dimethyl-, hydroxyethyl-, hydroxypropyl-, or sulfobutylether-beta-cyclodextrin. Hydroxypropylbetadex may preferably be used. Moreover, the concentration of the cyclodextrin derivative may preferably be 1.0 to 10.0 w/v%.
  • the amino acid that is another anti-recrystallizing agent of the present disclosure may comprise at least one selected from the group consisting of basic amino acids such as arginine, lysine, histidine, etc. and neutral amino acids such as glycine, alanine, valine, etc.
  • the concentration of the amino acid may preferably be 0.1 to 5.0 w/v%.
  • the buffering agent may comprise at least one selected from the group consisting of borate, phosphate, tromethamine, and mixtures thereof. Borate may preferably be used as the buffering agent. Moreover, the concentration of the buffering agent may preferably be 0.05 to 2.0 w/v%.
  • the ophthalmic composition of the present disclosure may further comprise at least one additive selected from the group consisting of a thickener, a solubilizing agent, an isotonic agent, and a pH adjusting agent.
  • the thickener is an additive that extends the amount of time a drug stays in the body during clinical application and may comprise at least one selected from the group consisting of polyvinylpyrrolidone, hydroxypropylmethylcellulose, and polyvinyl alcohol, but not limited thereto. Polyvinylpyrrolidone may preferably be used.
  • the solubilizing agent is an additive to increase the solubility of a drug and may comprise at least one selected from the group consisting of polyoxyl 35 hydrogenated castor oil, poloxamer, and polysorbate.
  • the isotonic agent may be added in an amount that makes the osmotic pressure of the ophthalmic solution similar to that of tears and may comprise chlorides, saccharides, propylene glycol, and glycerin.
  • the pH adjusting agent is an additive to adjust the pH in a range that is applicable to the body (eye) and does not injure the cornea and conjunctiva and may comprise inorganic acids or organic acids.
  • An inorganic acid such as phosphoric acid or phosphate may preferably be used.
  • the ophthalmic composition of the present disclosure may preferably have a pH of 7 to 8, which is in a physiologically neutral to weakly basic range that does not injure the cornea and conjunctiva of a patient suffering from dry eye.
  • the ophthalmic composition of the present disclosure has excellent transparency in the above pH range (pH 7 to 8), maintains its transparency even after standing for a long time, and has improved stability so as not to be re-dispersed.
  • the ophthalmic composition of the present disclosure is a solution formulation, rather than the existing aqueous suspension.
  • the ophthalmic composition of the present disclosure has solved the problem that it is difficult to manufacture in the form of a solution due to low solubility and, at the same time, has ensured the excellent transparency and stability. Therefore, the ophthalmic composition of the present disclosure may be very useful as an ophthalmic solution to patients suffering from dry eye.
  • the method for preparing an ophthalmic composition of the present disclosure comprises: a first step (S-1) of obtaining a solution by dissolving rebamipide in a buffer solution; a second step (S-2) of adding and dissolving an anti-recrystallizing agent selected from the group consisting of a cyclodextrin derivative, an amino acid, and mixtures thereof in the solution obtained in the first step; and a third step (S-3) of filtering the solution obtained in the second step through a sterile filter.
  • the second step may further comprise, after dissolving the anti-recrystallizing agent, the step of adding and dissolving at least one additive selected from the group consisting of a thickener, a solubilizing agent, an isotonic agent, and a pH adjusting agent.
  • a buffer solution of a suitable concentration is prepared by adding a buffering agent, and then rebamipide is added and dissolved in the buffer solution while stirring.
  • the pH adjusting agent may be added as necessary, and the anti-recrystallizing agent is added and dissolved in the transparent rebamipide solution while stirring.
  • the thickener, the solubilizing agent, the pH adjusting agent, and the isotonic agent may be added in appropriate concentrations according to circumstances. Moreover, all of these processes are achieved by simple stirring, and filtration is performed using a 0.22 ⁇ m sterile filter to achieve sterilization.
  • the manufacturing method of the present disclosure uses the anti-recrystallizing agent of rebamipide, such as the cyclodextrin derivative and/or amino acid, and the buffering agent to sufficiently maintain the transparency and prevent the formation of a precipitate layer even during long-term storage and can manufacture the ophthalmic composition comprising rebamipide by simple stirring without the use of expensive equipment.
  • the anti-recrystallizing agent of rebamipide such as the cyclodextrin derivative and/or amino acid
  • composition, and Method of preventing or treating dry eye syndrome are provided.
  • the present disclosure provides a pharmaceutical composition comprising the ophthalmic composition of the present disclosure.
  • the present disclosure also provides a pharmaceutical composition for treating dry eye syndrome comprising the ophthalmic composition of the present disclosure.
  • the present disclosure also provides a method of treating dry eye syndrome comprising an administration of the ophthalmic composition of the present disclosure to patients.
  • the ophthalmic composition of the present disclosure is prepared by mixing an anti-recrystallizing agent with a composition comprising rebamipide and a buffer solution, and thus it is possible to improve the transparency of the ophthalmic composition and maintain its transparency without aggregation or precipitation of dissolved particles even during long-term storage.
  • a transparent rebamipide ophthalmic solution by simple stirring without requiring complicated manufacturing processes such as high-pressure homogenization, ultrasonic dispersion, etc. by selecting a buffering agent suitable for the composition and adjusting the concentration of the buffer solution. Furthermore, it is possible to remove bacteria only by filtration using a 0.22 ⁇ m sterile filter, resulting in reduced manufacturing costs.
  • a buffering agent was added while stirring.
  • rebamipide was added and dissolved, and then hydroxypropylbetadex was added thereto.
  • a pH adjusting agent and an isotonic agent were added to adjust the pH level and the osmotic pressure.
  • the resulting rebamipide solution was filtered using a 0.22 ⁇ m sterile filter to prepare colorless transparent ophthalmic compositions of Examples 1 to 13.
  • compositions of Comparative Examples 1 to 5 were prepared by the same preparation method described in Examples 1 to 13, except for the process of adding hydroxypropylbetadex.
  • compositions I according to the composition of the buffering agent and hydroxypropylbetadex
  • compositions II according to the composition of the buffering agent and hydroxypropylbetadex
  • compositions of Examples 14 to 21 were prepared by the same preparation method described in Examples 1 to 13, except for varying the composition and ratio of amino acids as shown in the following table 3.
  • compositions of Examples 22 to 29 were prepared by the same preparation method described in Examples 1 to 13, except for varying the ratio of the thickener that can be further added to the ophthalmic composition comprising the anti-recrystallizing agent and the buffering agent as shown in the following table 4.
  • compositions of Examples 30 to 34 were prepared by the same preparation method described in Examples 1 to 13, except for varying the ratio of the solubilizing agent that can be further added to the composition comprising the anti-recrystallizing agent and the buffering agent as shown in the following table 5.
  • compositions prepared in Examples 1 to 13 and Comparative Examples 1 to 5 were stored at room temperature and under refrigeration, and then the presence or absence of crystal precipitation over time was determined and shown in the following tables 6 to 9.
  • compositions were observed with the naked eye using a tester for the Insoluble Particulate Matter Test for Ophthalmic Solutions of the Korean Pharmacopoeia.
  • the ophthalmic compositions of Examples 1 to 13 comprising the cyclodextrin derivative (hydroxypropylbetadex) that is an anti-recrystallizing agent were colorless and transparent even after standing for a long time, while precipitates were formed that does not comprise the anti-recrystallizing agent in the compositions of Comparative Examples 1 to 5 after 2 weeks.
  • compositions prepared in Examples 14 to 21 were stored at room temperature and under refrigeration, and then the presence or absence of crystal precipitation over time was determined by the same method as Experimental Example 1 and shown in the following tables 10 and 11.
  • the ophthalmic compositions of Examples 14 to 21 further comprising the amino acid also maintained the transparency (colorlessness) without any precipitate being formed.
  • compositions prepared in Examples 22 to 29 were stored at room temperature and under refrigeration, and then the presence or absence of crystal precipitation over time was determined by the same method as Experimental Example 1 and shown in the following tables 12 and 13.
  • compositions further comprising the thickener also maintained the transparency (colorlessness) and stability during the observation period.
  • compositions prepared in Examples 30 to 34 were stored at room temperature and under refrigeration, and then the presence or absence of crystal precipitation over time was determined by the same method as Experimental Example 1 and shown in the following tables 14 and 15.
  • compositions further comprising the solubilizing agent also maintained the transparency (colorlessness) and stability during the observation period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

The present disclosure provides a novel ophthalmic composition comprising rebamipide and a method for preparing the same. The ophthalmic composition of the present disclosure maintains its transparency for a long time even in a physiologically neutral to weakly basic pH range that does not injure the cornea and conjunctiva of a patient suffering from dry eye and has improved stability so as not to be re-dispersed.

Description

NOVEL OPHTHALMIC COMPOSITION COMPRISING REBAMIPIDE AND METHOD FOR PREPARING THE SAME
The present disclosure relates to an ophthalmic composition comprising rebamipide, which maintains its transparency, has excellent stability, and is easy to prepare, and a method for preparing the same.
Rebamipide [2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid] is a quinolone derivative represented by the following formula I.
[Formula I]
Figure PCTKR2016011015-appb-I000001
Rebamipide is known to increase gastric mucin to have anti-inflammatory and antiulcer actions on the digestive tract and thus has been used as an oral therapeutic agent for gastric ulcer since 1990. Moreover, the effects of rebamipide on an increase of goblet cell density in eyes, an increase of mucin in eyes, and an increase of lacrimal fluid have been proven, and thus rebamipide has been developed and sold as a therapeutic agent for dry eye syndrome in the form of an ophthalmic solution in Japan.
However, rebamipide has low solubility in a pH range where it is applicable to the eye, which makes it difficult to maintain a stable and transparent aqueous solution during long-term storage and to manufacture in the form of a transparent ophthalmic solution, and thus is available in the form of an ophthalmic suspension. Moreover, in the commercially available ophthalmic suspensions, the drug is dispersed as particles, which causes a feeling of irritation in the eye as well as local pain. Research aimed at developing a transparent ophthalmic solution comprising rebamipide has continued to progress; however, it is believed that it is difficult to develop an aqueous preparation comprising rebamipide so far, and the products developed so far are in the form of an ophthalmic suspension.
International Patent Publication No. WO 97/013515 discloses an aqueous suspension containing rebamipide. However, this suspension may form a flocculated suspension when standing for a long time. Therefore, the suspension needs to be shaken well to disperse the flocculated suspension. Moreover, the above suspension is a white suspension and thus may obscure the view.
International Patent Publication No. WO 2008/050896 discloses a rebamipide-containing aqueous suspension with improved suspensibility which can keep the dispersed fine-particle state of rebamipide stable without having the fine particle agglutinated, compared to the aqueous suspension of the above-mentioned International Patent Publication No. WO 97/013515. However, this suspension may also form a precipitate when standing for a long time and is a white suspension that obscures the view.
International Patent Publication No. WO 2006/052018 discloses an aqueous suspension containing crystalline rebamipide which has improved transparency, compared to the above-mentioned two aqueous suspensions. However, this invention requires expensive equipment such as a high-pressure homogenizer, a colloid mill, an ultrasonic device, etc. during manufacturing, the manufacturing process is very difficult and complicated, and the manufacturing time is long, resulting in high manufacturing costs. Moreover, it also has the problem that it forms a precipitate when standing for a long time.
International Patent Publication No. WO 2009/154304 and International Patent Publication No. WO 2014/051163 disclose transparent rebamipide ophthalmic compositions. However, these ophthalmic solutions have a high pH of 8 or higher and are not suitable for a patient suffering from an injury in cornea and conjunctiva such as dry eye.
Moreover, International Patent Publication No. WO 2008/074853 discloses a composition which uses a viscosity enhancer and a buffer to maintain the stability of an aqueous solution comprising rebamipide. However, this composition also has the problem that it forms a precipitate when standing for a long time.
Therefore, it is necessary to develop a pharmaceutical composition comprising rebamipide, which maintains its transparency for a long time even in a physiologically neutral to weakly basic pH range (below 8) that does not injure the cornea and conjunctiva of a patient suffering from dry eye, and which has improved stability so as not to be re-dispersed.
An object of the present disclosure is to provide an ophthalmic composition comprising rebamipide, which is transparent in a pH range of 7 to 8. More specifically, an object of the present disclosure is to provide an ophthalmic composition comprising rebamipide, which maintains its transparency for a long time even in a physiologically neutral to weakly basic pH range that does not injure the cornea and conjunctiva of a patient suffering from dry eye, and which has improved stability so as not to be re-dispersed.
Moreover, another object of the present disclosure is to provide a method for preparing an ophthalmic composition of the present disclosure in a simple manner without any complicated process.
In order to accomplish the objects of the present disclosure, the present disclosure provides a novel ophthalmic composition comprising rebamipide and a method for preparing the same, which will be described in detail below.
Ophthalmic Composition Comprising Rebamipide
The ophthalmic composition of the present disclosure comprises (1) rebamipide, (2) an anti-recrystallizing agent selected from the group consisting of a cyclodextrin derivative, an amino acid, and mixtures thereof, and (3) a buffering agent.
Rebamipide may be prepared directly by a conventionally known method or commercially available.
In the present disclosure, the concentration of rebamipide may be 0.1 to 1.5 w/v%, preferably 0.2 to 1.0 w/v%.
The anti-recrystallizing agent used in the present disclosure is an additive to prevent a solution, which is sufficiently transparent but is present in a supersaturated state, from failing to maintain a transparent appearance without any precipitate being formed during long-term storage. The anti-recrystallizing agent that can be used in the present disclosure includes a cyclodextrin derivative and/or an amino acid.
Examples of the cyclodextrin derivative used as the anti-recrystallizing agent in the present disclosure include alpha-, beta-, and gamma-cyclodextrin, and substituted derivatives thereof such as dimethyl-, hydroxyethyl-, hydroxypropyl-, or sulfobutylether-beta-cyclodextrin. Hydroxypropylbetadex may preferably be used. Moreover, the concentration of the cyclodextrin derivative may preferably be 1.0 to 10.0 w/v%.
The amino acid that is another anti-recrystallizing agent of the present disclosure may comprise at least one selected from the group consisting of basic amino acids such as arginine, lysine, histidine, etc. and neutral amino acids such as glycine, alanine, valine, etc. Moreover, the concentration of the amino acid may preferably be 0.1 to 5.0 w/v%.
In the present disclosure, the buffering agent may comprise at least one selected from the group consisting of borate, phosphate, tromethamine, and mixtures thereof. Borate may preferably be used as the buffering agent. Moreover, the concentration of the buffering agent may preferably be 0.05 to 2.0 w/v%.
Moreover, the ophthalmic composition of the present disclosure may further comprise at least one additive selected from the group consisting of a thickener, a solubilizing agent, an isotonic agent, and a pH adjusting agent.
The thickener is an additive that extends the amount of time a drug stays in the body during clinical application and may comprise at least one selected from the group consisting of polyvinylpyrrolidone, hydroxypropylmethylcellulose, and polyvinyl alcohol, but not limited thereto. Polyvinylpyrrolidone may preferably be used.
The solubilizing agent is an additive to increase the solubility of a drug and may comprise at least one selected from the group consisting of polyoxyl 35 hydrogenated castor oil, poloxamer, and polysorbate.
The isotonic agent may be added in an amount that makes the osmotic pressure of the ophthalmic solution similar to that of tears and may comprise chlorides, saccharides, propylene glycol, and glycerin.
The pH adjusting agent is an additive to adjust the pH in a range that is applicable to the body (eye) and does not injure the cornea and conjunctiva and may comprise inorganic acids or organic acids. An inorganic acid such as phosphoric acid or phosphate may preferably be used.
The ophthalmic composition of the present disclosure may preferably have a pH of 7 to 8, which is in a physiologically neutral to weakly basic range that does not injure the cornea and conjunctiva of a patient suffering from dry eye.
Moreover, the ophthalmic composition of the present disclosure has excellent transparency in the above pH range (pH 7 to 8), maintains its transparency even after standing for a long time, and has improved stability so as not to be re-dispersed.
According to a preferred embodiment of the present disclosure, the ophthalmic composition of the present disclosure is a solution formulation, rather than the existing aqueous suspension. The ophthalmic composition of the present disclosure has solved the problem that it is difficult to manufacture in the form of a solution due to low solubility and, at the same time, has ensured the excellent transparency and stability. Therefore, the ophthalmic composition of the present disclosure may be very useful as an ophthalmic solution to patients suffering from dry eye.
Method for Preparing Ophthalmic Composition Comprising Rebamipide
The method for preparing an ophthalmic composition of the present disclosure comprises: a first step (S-1) of obtaining a solution by dissolving rebamipide in a buffer solution; a second step (S-2) of adding and dissolving an anti-recrystallizing agent selected from the group consisting of a cyclodextrin derivative, an amino acid, and mixtures thereof in the solution obtained in the first step; and a third step (S-3) of filtering the solution obtained in the second step through a sterile filter.
Moreover, the second step may further comprise, after dissolving the anti-recrystallizing agent, the step of adding and dissolving at least one additive selected from the group consisting of a thickener, a solubilizing agent, an isotonic agent, and a pH adjusting agent.
Specifically, a buffer solution of a suitable concentration is prepared by adding a buffering agent, and then rebamipide is added and dissolved in the buffer solution while stirring. The pH adjusting agent may be added as necessary, and the anti-recrystallizing agent is added and dissolved in the transparent rebamipide solution while stirring. The thickener, the solubilizing agent, the pH adjusting agent, and the isotonic agent may be added in appropriate concentrations according to circumstances. Moreover, all of these processes are achieved by simple stirring, and filtration is performed using a 0.22 ㎛ sterile filter to achieve sterilization.
The manufacturing method of the present disclosure uses the anti-recrystallizing agent of rebamipide, such as the cyclodextrin derivative and/or amino acid, and the buffering agent to sufficiently maintain the transparency and prevent the formation of a precipitate layer even during long-term storage and can manufacture the ophthalmic composition comprising rebamipide by simple stirring without the use of expensive equipment.
Pharmaceutical composition, and Method of preventing or treating dry eye syndrome
The present disclosure provides a pharmaceutical composition comprising the ophthalmic composition of the present disclosure.
The present disclosure also provides a pharmaceutical composition for treating dry eye syndrome comprising the ophthalmic composition of the present disclosure.
The present disclosure also provides a method of treating dry eye syndrome comprising an administration of the ophthalmic composition of the present disclosure to patients.
The ophthalmic composition of the present disclosure is prepared by mixing an anti-recrystallizing agent with a composition comprising rebamipide and a buffer solution, and thus it is possible to improve the transparency of the ophthalmic composition and maintain its transparency without aggregation or precipitation of dissolved particles even during long-term storage.
Moreover, according to the present disclosure, it is possible to manufacture a transparent rebamipide ophthalmic solution by simple stirring without requiring complicated manufacturing processes such as high-pressure homogenization, ultrasonic dispersion, etc. by selecting a buffering agent suitable for the composition and adjusting the concentration of the buffer solution. Furthermore, it is possible to remove bacteria only by filtration using a 0.22 ㎛ sterile filter, resulting in reduced manufacturing costs.
Hereinafter, Examples and Experimental Examples of the present disclosure will be described below for better understanding of the present disclosure, but the scope of the present disclosure is not limited by the Examples and Experimental Examples.
Examples 1 to 13 and Comparative Examples 1 to 5
According to the composition and ratio of components shown in the following tables 1 and 2, to purified water of appropriate volume, a buffering agent was added while stirring. To the buffer solution while stirring, rebamipide was added and dissolved, and then hydroxypropylbetadex was added thereto. After the rebamipide and hydroxypropylbetadex were completely dissolved, a pH adjusting agent and an isotonic agent were added to adjust the pH level and the osmotic pressure. The resulting rebamipide solution was filtered using a 0.22 ㎛ sterile filter to prepare colorless transparent ophthalmic compositions of Examples 1 to 13.
According to the composition and ratio of components shown in the following tables 1 and 2, compositions of Comparative Examples 1 to 5 were prepared by the same preparation method described in Examples 1 to 13, except for the process of adding hydroxypropylbetadex.
[Table 1] Compositions I according to the composition of the buffering agent and hydroxypropylbetadex
Figure PCTKR2016011015-appb-I000002
[Table 2] Compositions II according to the composition of the buffering agent and hydroxypropylbetadex
Figure PCTKR2016011015-appb-I000003
Examples 14 to 21
Compositions of Examples 14 to 21 were prepared by the same preparation method described in Examples 1 to 13, except for varying the composition and ratio of amino acids as shown in the following table 3.
[Table 3] Compositions according to the composition and ratio of amino acids
Figure PCTKR2016011015-appb-I000004
Examples 22 to 29
Compositions of Examples 22 to 29 were prepared by the same preparation method described in Examples 1 to 13, except for varying the ratio of the thickener that can be further added to the ophthalmic composition comprising the anti-recrystallizing agent and the buffering agent as shown in the following table 4.
[Table 4] Compositions according to the ratio of thickeners
Figure PCTKR2016011015-appb-I000005
Examples 30 to 34
Compositions of Examples 30 to 34 were prepared by the same preparation method described in Examples 1 to 13, except for varying the ratio of the solubilizing agent that can be further added to the composition comprising the anti-recrystallizing agent and the buffering agent as shown in the following table 5.
[Table 5] Compositions according to the ratio of solubilizing agents
Figure PCTKR2016011015-appb-I000006
Experimental Example 1
In order to evaluate the transparency and stability depending on the presence or absence of the anti-recrystallizing agent, the compositions prepared in Examples 1 to 13 and Comparative Examples 1 to 5 were stored at room temperature and under refrigeration, and then the presence or absence of crystal precipitation over time was determined and shown in the following tables 6 to 9.
The transparency of the compositions was observed with the naked eye using a tester for the Insoluble Particulate Matter Test for Ophthalmic Solutions of the Korean Pharmacopoeia.
[Table 6] Evaluation of Stability at Room Temperature of Examples 1 to 13
Figure PCTKR2016011015-appb-I000007
[Table 7] Evaluation of Stability at Room Temperature of Comparative Examples 1 to 5
Figure PCTKR2016011015-appb-I000008
[Table 8] Evaluation of Stability under Refrigeration of Examples 1 to 13
Figure PCTKR2016011015-appb-I000009
[Table 9] Evaluation of Stability under Refrigeration of Comparative Examples 1 to 3
Figure PCTKR2016011015-appb-I000010
As shown in tables 6 to 9, the ophthalmic compositions of Examples 1 to 13 comprising the cyclodextrin derivative (hydroxypropylbetadex) that is an anti-recrystallizing agent were colorless and transparent even after standing for a long time, while precipitates were formed that does not comprise the anti-recrystallizing agent in the compositions of Comparative Examples 1 to 5 after 2 weeks.
Experimental Example 2
In order to determine the availability of amino acids as an anti-recrystallizing agent, the compositions prepared in Examples 14 to 21 were stored at room temperature and under refrigeration, and then the presence or absence of crystal precipitation over time was determined by the same method as Experimental Example 1 and shown in the following tables 10 and 11.
[Table 10] Evaluation of Stability at Room Temperature of Examples 14 to 21
Figure PCTKR2016011015-appb-I000011
[Table 11] Evaluation of Stability under Refrigeration of Examples 14 to 21
Figure PCTKR2016011015-appb-I000012
As a result of the experiment, the ophthalmic compositions of Examples 14 to 21 further comprising the amino acid also maintained the transparency (colorlessness) without any precipitate being formed.
Experimental Example 3
In order to determine the effect of the addition of thickener, the compositions prepared in Examples 22 to 29 were stored at room temperature and under refrigeration, and then the presence or absence of crystal precipitation over time was determined by the same method as Experimental Example 1 and shown in the following tables 12 and 13.
[Table 12] Evaluation of Stability at Room Temperature of Examples 22 to 29
Figure PCTKR2016011015-appb-I000013
[Table 13] Evaluation of Stability under Refrigeration of Examples 22 to 29
Figure PCTKR2016011015-appb-I000014
As a result of the experiment, it was observed that the compositions further comprising the thickener also maintained the transparency (colorlessness) and stability during the observation period.
Experimental Example 4
In order to determine the effect of the addition of solubilizing agent, the compositions prepared in Examples 30 to 34 were stored at room temperature and under refrigeration, and then the presence or absence of crystal precipitation over time was determined by the same method as Experimental Example 1 and shown in the following tables 14 and 15.
[Table 14] Evaluation of Stability at Room Temperature of Examples 30 to 34
Figure PCTKR2016011015-appb-I000015
[Table 15] Evaluation of Stability under Refrigeration of Examples 30 to 34
Figure PCTKR2016011015-appb-I000016
As a result of the experiment, it was observed that the compositions further comprising the solubilizing agent also maintained the transparency (colorlessness) and stability during the observation period.

Claims (13)

  1. An ophthalmic composition comprising:
    (1) rebamipide;
    (2) an anti-recrystallizing agent selected from the group consisting of a cyclodextrin derivative, an amino acid, and mixtures thereof; and
    (3) a buffering agent.
  2. The ophthalmic composition of claim 1, wherein the concentration of rebamipide is 0.1 to 1.5 w/v%.
  3. The ophthalmic composition of claim 1, wherein the cyclodextrin derivative is hydroxypropylbetadex.
  4. The ophthalmic composition of claim 1, wherein the concentration of the cyclodextrin derivative is 1.0 to 10.0 w/v%.
  5. The ophthalmic composition of claim 1, wherein the amino acid is selected from the group consisting of arginine, lysine, histidine, glycine, alanine, valine, and mixtures thereof.
  6. The ophthalmic composition of claim 1, wherein the concentration of the amino acid is 0.1 to 5.0 w/v%.
  7. The ophthalmic composition of claim 1, wherein the buffering agent is selected from the group consisting of borate, phosphate, tromethamine, and mixtures thereof.
  8. The ophthalmic composition of claim 1, wherein the concentration of the buffering agent is 0.05 to 2.0 w/v%.
  9. The ophthalmic composition of any one of claims 1 to 8, further comprising at least one additive selected from the group consisting of a thickener, a solubilizing agent, an isotonic agent, and a pH adjusting agent.
  10. The ophthalmic composition of claim 1, wherein the pH range of the ophthalmic composition is 7 to 8.
  11. The ophthalmic composition of claim 1, wherein the composition is a solution.
  12. A method for preparing an ophthalmic composition,
    wherein the method comprises:
    a first step (S-1) of obtaining a solution by dissolving rebamipide in a buffer solution;
    a second step (S-2) of adding and dissolving an anti-recrystallizing agent selected from the group consisting of a cyclodextrin derivative, an amino acid, and mixtures thereof in the solution obtained in the first step; and
    a third step (S-3) of filtering the solution obtained in the second step through a sterile filter.
  13. The method of claim 12, wherein the second step comprises, after dissolving the anti-recrystallizing agent, the step of adding and dissolving at least one additive selected from the group consisting of a thickener, a solubilizing agent, an isotonic agent, and a pH adjusting agent.
PCT/KR2016/011015 2015-10-01 2016-09-30 Novel ophthalmic composition comprising rebamipide and method for preparing the same WO2017057973A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2018516690A JP6625206B2 (en) 2015-10-01 2016-09-30 New ophthalmic composition containing rebamipide and method for producing the same {Novel opalmic composition combining rebamide and method for preparing the same}
BR112018006474A BR112018006474A2 (en) 2015-10-01 2016-09-30 new ophthalmic composition comprising rebamipide and method for preparing the same
US15/762,165 US10918725B2 (en) 2015-10-01 2016-09-30 Ophthalmic composition comprising rebamipide and method for preparing the same
EP16852119.3A EP3355929A4 (en) 2015-10-01 2016-09-30 Novel ophthalmic composition comprising rebamipide and method for preparing the same
MX2018003799A MX2018003799A (en) 2015-10-01 2016-09-30 Novel ophthalmic composition comprising rebamipide and method for preparing the same.
CA3000634A CA3000634C (en) 2015-10-01 2016-09-30 Novel ophthalmic composition comprising rebamipide and method for preparing the same
CN201680056205.9A CN108136036A (en) 2015-10-01 2016-09-30 Novel ophthalmic composition comprising Rebamipide and preparation method thereof
RU2018115669A RU2706353C1 (en) 2015-10-01 2016-09-30 Novel ophthalmic composition containing rebamipide, and method for production thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0138349 2015-10-01
KR1020150138349A KR20170039347A (en) 2015-10-01 2015-10-01 Novel opthalmic composition comprising rebamipide and method for preparing the same

Publications (1)

Publication Number Publication Date
WO2017057973A1 true WO2017057973A1 (en) 2017-04-06

Family

ID=58423846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/011015 WO2017057973A1 (en) 2015-10-01 2016-09-30 Novel ophthalmic composition comprising rebamipide and method for preparing the same

Country Status (10)

Country Link
US (1) US10918725B2 (en)
EP (1) EP3355929A4 (en)
JP (1) JP6625206B2 (en)
KR (1) KR20170039347A (en)
CN (1) CN108136036A (en)
BR (1) BR112018006474A2 (en)
CA (1) CA3000634C (en)
MX (1) MX2018003799A (en)
RU (1) RU2706353C1 (en)
WO (1) WO2017057973A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200019451A (en) 2018-08-14 2020-02-24 대우제약 주식회사 A water-soluble, multi-use eyedrops composition for the treatment of dry eye syndrome containing rebamipide and a method for solubilization and stabilization thereof
KR102615076B1 (en) 2021-07-14 2023-12-19 대우제약 주식회사 Method for preparing stable rebamipide eye drop on large scale

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US20070287729A1 (en) * 2004-11-15 2007-12-13 Otsuka Pharmaceutical Co., Ltd. Aqueous Ophthalmic Suspension of Crystalline Rebamipide
US20100029714A1 (en) * 2006-10-26 2010-02-04 Yoshito Masuda Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
US20110124682A1 (en) * 2008-06-19 2011-05-26 Sumida Shun-Ichiro Pharmaceutical composition comprising rebamipide
US20140294991A1 (en) * 2011-11-01 2014-10-02 Otsuka Pharmaceutical Co., Ltd. Medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0616547A (en) 1992-07-01 1994-01-25 Wakamoto Pharmaceut Co Ltd Antiphlogistic ophthalmic solution
AR004214A1 (en) 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd A PREPARATION OF OPHTHALMIC DROPS FOR THE CURE OF OPHTHALMIC DISEASES
KR20040104020A (en) * 2003-06-02 2004-12-10 진양제약주식회사 A new rebamipide lysinate, rebamipide argininate and pharmaceutical preparation containing the same as active substance
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
CN101081211A (en) 2006-06-02 2007-12-05 北京万鹏朗格医药科技有限公司 Water indissoluble carbostyrile compound injection and method for preparing the same
WO2008074853A1 (en) 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
WO2009022674A1 (en) * 2007-08-10 2009-02-19 Otsuka Pharmaceutical Co., Ltd. Medical composition containing rebamipide
CA2715802A1 (en) 2008-02-28 2009-09-03 Bial - Portela & C.A., S.A. Pharmaceutical composition for poorly soluble drugs
CN101757621B (en) 2008-11-28 2012-07-04 天津金耀集团有限公司 Cyclodextrin inclusion drug composition for ocular inflammation resistance
JP5639409B2 (en) 2009-08-07 2014-12-10 ロート製薬株式会社 Ophthalmic composition for silicone hydrogel contact lens
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
CN102512420A (en) * 2011-11-29 2012-06-27 北京阜康仁生物制药科技有限公司 Officinal composite using Rebamipide officinal salt as active ingredient
TW201417814A (en) 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd Pharmaceutical composition comprising rebamipide
CN104586762A (en) 2014-04-11 2015-05-06 广州仁恒医药科技有限公司 Rebamipide-containing drug composition and preparation method thereof
CN105147606A (en) * 2015-08-18 2015-12-16 广州仁恒医药科技有限公司 Preparation method of rebamipide aqueous suspension
KR101718733B1 (en) 2015-08-21 2017-03-22 국제약품 주식회사 Method for solubilizing Rebamipide and a solution for treating dry eye syndrome prepared thereby

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US20070287729A1 (en) * 2004-11-15 2007-12-13 Otsuka Pharmaceutical Co., Ltd. Aqueous Ophthalmic Suspension of Crystalline Rebamipide
US20100029714A1 (en) * 2006-10-26 2010-02-04 Yoshito Masuda Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
US20110124682A1 (en) * 2008-06-19 2011-05-26 Sumida Shun-Ichiro Pharmaceutical composition comprising rebamipide
US20140294991A1 (en) * 2011-11-01 2014-10-02 Otsuka Pharmaceutical Co., Ltd. Medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3355929A4 *

Also Published As

Publication number Publication date
BR112018006474A2 (en) 2018-10-09
EP3355929A4 (en) 2019-06-19
JP6625206B2 (en) 2019-12-25
US10918725B2 (en) 2021-02-16
EP3355929A1 (en) 2018-08-08
RU2706353C1 (en) 2019-11-18
KR20170039347A (en) 2017-04-11
JP2018531934A (en) 2018-11-01
CA3000634C (en) 2020-05-05
CN108136036A (en) 2018-06-08
CA3000634A1 (en) 2017-04-06
US20180264120A1 (en) 2018-09-20
MX2018003799A (en) 2018-09-12

Similar Documents

Publication Publication Date Title
JPH07116029B2 (en) Tranilast aqueous solution formulation
WO2018056720A1 (en) Injectable composition having enhanced stability
WO2017057973A1 (en) Novel ophthalmic composition comprising rebamipide and method for preparing the same
KR20200044873A (en) Eye pharmaceutical composition
WO2012074244A2 (en) Injectable liquid composition or injectable dried powder containing revaprazan or its salt
WO2018155773A1 (en) Composition, for preventing or treating dry eye syndrome, containing polyethylene glycol and flavonoid nanocomposite as active ingredient
EP3648739A1 (en) Composition for injection
WO2021049825A1 (en) Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof
WO2013147452A1 (en) Pharmaceutical composition in form of non-aqueous liquid comprising revaprazan or its salt
WO2020004784A1 (en) Aqueous multi-use eye drop composition for treatment of dry eye syndrome comprising rebamipide, and method for solubilizing and stabilizing same
WO2019059479A1 (en) Novel eye drop composition for treating dry eye syndrome containing rebamipide and method for solubilizing and stabilizing same
Kala et al. Formulation and evaluation of besifloxacin loaded in situ gel for ophthalmic delivery
JPH0930966A (en) New pharmaceutical preparation for eye
WO2018111021A1 (en) Ophthalmic composition containing sulfasalazine and hyaluronic acid
KR920002329B1 (en) Apply eyewash drug of anti-allergy
WO2021261930A1 (en) Ophthalmic composition comprising diquafosol
KR102307958B1 (en) Novel opthalmic composition comprising rebamipide and method for preparing the same
WO2022158893A2 (en) Ophthalmic composition
WO2016153304A1 (en) Preparation comprising indole compound and process for preparing the same
WO2011031100A2 (en) Aripiprazole-bentonite-aea hybrid, pharmaceutical composition containing the same and method for preparing the same
WO2012074243A2 (en) Injectable liquid composition containing revaprazan or its salt
WO2019168289A1 (en) Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof
WO2019107986A1 (en) Pharmaceutical composition comprising fimasartan
JP3814833B2 (en) Formulation consisting of pranlukast and polyvinylpyrrolidone or β-cyclodextrin
WO2010008135A1 (en) Oral soft capsule of aceclofenac having improved stability

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16852119

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15762165

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/003799

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 3000634

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2018516690

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018006474

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2016852119

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2018115669

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 112018006474

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180329